Helix BioPharma Corp. will present at the Q3 2025 Investor Summit Virtual on September 16, 2025, focusing on its clinical development pipeline and strategic corporate milestones. The company, a clinical-stage oncology firm, will detail preparations for a Phase Ib/Randomized Phase II study of L-DOS47 combined with pembrolizumab for first-line non-small cell lung cancer (NSCLC) treatment. This combination therapy aims to enhance the effectiveness of existing anti-cancer treatments by targeting CEACAM6-expressing tumors, potentially improving outcomes for patients with this challenging cancer type.
Additionally, Helix plans to discuss its anticipated uplisting to NASDAQ in Q1 2026, a move intended to increase visibility and access to global capital markets. These initiatives reflect the company's broader strategy to accelerate oncology asset development and transform hard-to-treat cancers into manageable conditions. Investors attending the virtual event can register for free at https://investorsummitgroup.fillout.com/t/8CZGk3gSQbus to gain insights directly from CEO Thomas Mehrling, MD, PhD, during one-on-one meetings.
The Investor Summit, organized by Investor Summit Group, serves as a platform for connecting undervalued microcap companies with institutional investors and high-net-worth individuals. Helix's presentation, scheduled for September 16 at 2:30 PM ET, will be accessible via webcast at https://investorsummitgroup.com/presentor/q3-track-1-helix-biopharma-corp/. This event emphasizes companies with strong growth catalysts, aligning with Helix's ongoing clinical progress and corporate expansion efforts.
Helix's pipeline includes L-DOS47, an antibody-enzyme conjugate designed to sensitize tumors to therapy, alongside pre-IND candidates LEUMUNA™ for post-transplant leukemia relapse and GEMCEDA™, an oral gemcitabine prodrug. These developments could significantly impact oncology treatment paradigms, offering new options for patients with limited alternatives. The company's focus on near-term solutions for hard-to-treat cancers underscores the potential industry-wide implications of its research, potentially influencing future therapeutic approaches and investment in oncology innovation.
